CCL5 Induces a Sarcopenic-like Phenotype via the CCR5 Receptor by Francisco Aguirre, Franco Tacchi, Mayalen Valero-Breton, Josué Orozco-Aguilar, Sabrina Conejeros-Lillo, Josefa Bonicioli, Renata Iturriaga-Jofré, Daniel Cabrera, Jorge A. Soto, Mauricio Castro-Sepúlveda, Marianny Portal-Rodríguez, Álvaro A. Elorza, Andrea Matamoros, Felipe Simon, Claudio Cabello-Verrugio

Get full text

Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase by Takeshi Iwasaki, Takeshi Iwasaki, Hajime Yoshifuji, Koji Kitagori, Shuji Sumitomo, Shuji Akizuki, Ran Nakashima, Hideaki Tsuji, Ryosuke Hiwa, Mirei Shirakashi, Kosaku Murakami, Akira Onishi, Hideo Onizawa, Masao Tanaka, Fumihiko Matsuda, Akio Morinobu, Koichiro Ohmura, Koichiro Ohmura

Get full text

Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content by Baohua Luo, Qingling An, Jingyu Lei, Dengxu Tan, Xiaoqiu Liu, Hui Li, Yong Zhao, Jing Qin, Caiqin Zhang, Yongbin Zhang, Changhong Shi

“…Recent studies have indicated that the combination of intestinal microflora regulators and ICI may be an effective strategy for enhancing the response to tumor immunotherapy. Resveratrol has been shown to regulate both intestinal microbiota and the immune microenvironment; therefore, we speculated that resveratrol may enhance the immunotherapeutic effect of α-PD-1 on PC. …”
Get full text

Integrative prognostic modeling of ovarian cancer: incorporating genetic, clinical, and immunological markers by Aidi Lin, Feifei Xue, Chenxiang Pan, Lijiao Li

“…High-risk patients demonstrated poor prognosis, greater immune checkpoint expression, and higher tumor mutational burdens (TMB), suggesting potential responsiveness to immunotherapy. The model's predictive capacity was validated across multiple cohorts, showing consistent performance in survival prediction and treatment response. …”
Get full text

Intratumor heterogeneity in KRAS signaling shapes treatment resistance by Oleksi Petrenko, Varvara Kirillov, Stephen D'Amico, Nancy C. Reich

“…Selective targeting of mutant KRAS suppresses the growth of tumor cells with high RAS/mitogen-activated protein kinase (MAPK) activity while sparing pre-existing subsets with low RAS signaling activity, necessitating alternative treatments. Combination immunotherapy leads to durable tumor regression in preclinical models.…”
Get full text

Nanocarriers-Assisted Nose-to-Brain Delivery of Levodopa: Current Progress and Prospects by Mariya Dangova, Nadezhda Ivanova, Velichka Andonova

“…While the potential century’s break-through is sought and foreseen by many scientists in gene therapy, immunotherapy, new drug combinations, and neurosurgical approaches, the not-yet-conventional intranasal administration of “classic” levodopa (L-DOPA) also stands out as a perspective from which Parkinson’s patients may benefit in the short term. …”
Get full text

Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn’s Disease: A 9-Year Survival by Jiten P. Kothadia, Deepa H. Nagaraju, Seymour Katz, Howard Bruckner, Steven H. Itzkowitz, Myron Schwartz

“…Our case describes serial promising treatment options of these advanced malignancies and raises a possible role for checkpoint immunotherapy.…”
Get full text

Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers by Ruishan Liu, Shemra Rizzo, Lisa Wang, Nayan Chaudhary, Sophia Maund, Marius Rene Garmhausen, Sarah McGough, Ryan Copping, James Zou

“…We systematically identified 776 genomic alterations associated with survival outcomes across 20 distinct cancer types treated with specific immunotherapies, chemotherapies, or targeted therapies. …”
Get full text

Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma by Fabio Morandi, Francesco Frassoni, Mirco Ponzoni, Chiara Brignole

“…In the last two decades, a strong effort has been spent in the field of translational research of immunotherapy which led to satisfactory results. Indeed, several immunotherapeutic clinical trials have been performed and some of them also resulted beneficial. …”
Get full text

Advances in sodium-glucose transporter protein 2 inhibitors and tumors by Jiaqi Wang, Wenyong Yang

“…Although the clinical application of targeted therapy and immunotherapy has improved the status quo of tumor treatment, the development of new therapeutic tools for tumors is still necessary. …”
Get full text

A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System by Mario García-Domínguez

Get full text

Heterogeneity in NK Cell Subpopulations May Be Involved in Kidney Cancer Metastasis by Zhengfang Liang, Fengwei Nong, Jingjie Zhao, Dalong Wei, Qianli Tang, Jian Song, Lingzhang Meng

“…Although substantial progress has been made in the immunotherapy of kidney cancer, its efficacy varies from patient to patient, with many responding suboptimally or even developing metastases. …”
Get full text

Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities by Mohammad Burhan Uddin, Zhishan Wang, Chengfeng Yang

“…Abstract Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although the development of resistance is often reported along with temporary disease remission, there is often tumor recurrence of an even more aggressive nature. …”
Get full text

Transitory Spontaneous Remission of Myelodysplasia in an Elderly Man while Receiving Intravesical Bacillus Calmette-Guérin for Bladder Cancer: A Case Report and Review of the Liter... by Nigel P. Murray, Cynthia Fuentealba, Isidora Salazar, Aníbal Salazar, Marco Antonio Lopez, Simona Minzer

“…Intravescial BCG is standard immunotherapy for superficial bladder cancer. We present a patient with transfusion-dependent myelodysplasia whose blood counts normalized during treatment with intravesical BCG for bladder cancer. …”
Get full text

Sirolimus for the Treatment of Airway Obstruction due to Indolent T-Lymphoblastic Proliferation by Eric Moughames, Ana P. Kiess, Lee M. Akst, Antoine Azar

“…Trials of radiotherapy and immunotherapy with cyclosporine and rituximab all failed to control the progression of the disease. …”
Get full text

Colorectal Metastasis From Lung Adenocarcinoma With Initial Gastrointestinal Symptoms: A Case Report and Literature Review by Yu Xin, Dan Liu, Dan Zang, Yan Sun, Jun Chen

“…This report describes an uncommon case of lung adenocarcinoma that metastasized to the colon with initial symptoms involving the GI tract. After immunotherapy, the condition was stable for more than 2 years, and he is currently in good condition.…”
Get full text

Synopsis of colorectal cancer: prevalence, symptoms, screening, staging, risk factors, and treatment by Gehan F. Balata, Hany N. Azzam

“…Management differs depending on stage: stages 0 and I are treated with endoscopy and local excision, whereas stages II, III, and IV necessitate systemic treatments like immunotherapy, targeted therapy, and chemotherapy.…”
Get full text

Improving TCR Gene Therapy for Treatment of Haematological Malignancies by Emma Nicholson, Sara Ghorashian, Hans Stauss

“…Adoptive immunotherapy using TCR gene modified T cells may allow separation of beneficial Graft versus tumour responses from harmful GvHD. …”
Get full text

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma by Caroline Y. K. Fong, Emma Burke, David Cunningham, Naureen Starling

“…Furthermore, it will explore newer approaches anticipated to come to the fore of future clinical practice, such as agents targeting the DNA damage response and tumour microenvironment as well as immunotherapy-based combinations.…”
Get full text

Ignoring Gender-Based Immunometabolic Reprograming, a Risky Business in Immune-Based Precision Medicine by Vijay Kumar

Get full text